CIK 0001841387 · <br>Emerging growth company
Candel Therapeutics, Inc.
Sign in to watch- Ticker
- CADL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 522214851
- Phone
- 617-916-5445
- Business address
- 117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 8-K Event Regulation FD disclosure
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Material agreement · Results of operations · New debt or obligation · Unregistered share sale · Regulation FD disclosure · Other events
- EFFECT Other Notice of Effectiveness
- 8-K Event Material agreement
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Chief Medical Officer sold 937 shares at $6.98 ($6,540)
- 4 Planned sale Chief Medical Officer sold 781 shares at $5.04 ($3,936)
- 144 Insider Sale of Securities
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Grant or award Chief Technology Officer acquired 5,353 shares (grant or award)
Page 4 of 21 · 420 filings